XXXIst
EDITION
20 > 22.02.19
HILTON HOTEL ANTWERPEN

www.bwge.be
Dear Colleagues,

It is our pleasure to welcome you to the XXXIth Edition of the Belgian Week of Gastroenterology. Enclosed you will find the complete program of this meeting. We are pleased we can offer you once again a variety of high quality scientific meetings combining the presentation of cutting-edge research performed at our Belgian institutions as well as state-of-the-art lectures by renowned experts on a wide range of topics, relevant to our field and its various subdisciplines.

Besides these scientific sections that constitute the backbone of the congress for many years, the BWGE 2019 offers a lot of other attractive sessions and activities!

As for the latest edition, the program starts already on Wednesday 20th February with a brand new initiative: the BWGE Postgraduate Course. The speakers of the PGC will focus on new diagnostic and therapeutic insights into a specific gastrointestinal disorder with direct impact on daily clinical practice. The program is oriented towards clinical gastroenterologists, fellows and trainees and is part of a 3-year postgraduate program covering all fields and updates in our specialty. This PGC hence fits well within the aim of the BWGE: bringing together clinicians and researchers in a stimulating meeting.

We also invite you to attend the satellite symposia, organized by some of our sponsors, featuring top-experts for exciting talks or panel discussions.

Posters will be permanently displayed on interactive screens in the exhibition hall. Some of the best posters will be discussed during lunchtime in a separate area in the exhibition hall. We encourage you to attend these sessions and support our young researchers.

This year’s ultrasound course on Thursday covers basic abdominal ultrasonography, with the possibility to train on healthy volunteers.

The Belgian Society of Gastrointestinal Endoscopy organises for the third time a live endoscopy session, scheduled on Friday morning as part of the PGC, followed in the afternoon by the session of the Working Group of Proctology, launched last year, who has again an exciting clinical program to offer.

The Young Belgian Association for the Study of the Liver participates with an ethics and economy-accreditated scientific session on Wednesday afternoon.

During the Interactive Case Report Session on Thursday morning, interesting and rare cases will be discussed and commented on.

Do not forget to join us for the award ceremony and evening party (with an opening concert!) on Thursday evening at the Felix Pakhuis!!

We hope you will enjoy a stimulating scientific meeting!

Sven FRANCOUE and Isabelle COLLE
Scientific Coordinators of the Belgian Week of Gastroenterology

All abstracts will be published in Acta Gastroenterologica Belgica. Acta Gastroenterologica is accessible on internet: www.acta-gastroenterologica.be

Editor-in-Chief: Tom MOREELS / Nicolas LANTHIER

For more information please send mail to info@bayer.be

* Nex2You: for patients receiving Sorafenib.
* Stiv@Home: for patients receiving Regorafenib.
INDEX

WELCOME 3
INDEX 4
GENERAL INFORMATION 6
STEERING COMMITTEE 7
SATELLITE SYMPOSIA 8
INVITED LECTURES 10

WEDNESDAY FEBRUARY 20
Postgraduate Course 12
BIRD Basic 15
e-POSTER SESSION BIRD 19
Belgian Pancreatic Club 21
YOUNG BASL 23

THURSDAY FEBRUARY 21
BASL 25
e-POSTER SESSION BASL 31
BIRD CLINICAL 35
PROGRAM OVERVIEW 38-39
e-POSTER SESSION BSGIE 42
BSGIE 44
GIREM 46
e-POSTER SESSION GIREM 49
Case Report Session 50
ULTRA SOUND Course 52
GRANTS & PRIZES 53
DINNER & PARTY 54

FRIDAY FEBRUARY 22
BGDO 56
e-POSTER SESSION BGDO 60
Working Group of Digestive Pathology 62
BSGIE LIVE SESSION 66
BeSPGHAN 68
e-POSTER SESSION BeSPGHAN 69
Belgian Working Group on Proctology 70

SAVE THE DATE 72

31 ST EDITION

20 > 22.02.19
GENERAL INFORMATION

ACCREDITATION
CME credits will be provided by online submission to the registered delegates who have attended the sessions. The number of credits is 6 credits points per day (category 3). The file from the online accreditation registrations will be sent to the INAMI/ RIZIV end of March 2019.

LANGUAGES
Dutch, French and English. English (British spelling) for abstracts, slides and announcements. As proposed at the Steering Committee of 1995, Belgian authors may present their original papers in their mother tongue.

VENUE
HILTON ANTWERPEN
Groenplaats, 32 - 2000 Antwerpen
Tel: +32 3 204 12 12
Website: www.antwerp.hilton.com

PARKING
Here are the closest parkings to the Hilton Antwerp : parking fees are the responsibility of the participants.
• Groenplaats Parking: The Hilton Antwerp has reserved 200 places for our congress.
• Meir Parking
• Brabo Parking
• Lombardia Parking

EVENT COORDINATOR / SCIENTIFIC SECRETARY
DME-EVENTS - ANNE-FRANCE DE MEYER
57 av. G. Demeylaan - 1160 Bruxelles / Brussel
Tel. +32 477 27 00 45
E-mail: anne.france.de.meyer@dme-events.eu

STEERING COMMITTEE

SCIENTIFIC COORDINATORS
Sven FRANQUÉ - Isabelle COLLE

SEVEN SOCIETIES
VVGE
Vlaamse Vereniging voor Gastroenterologie
P. Caenepeel, M. Peeters, H. Reynaert

SRBG
Société Royale Belge de Gastroenterologie
C. Van Kemseke, G. Verset

BSGIE
Belgian Society of Gastrointestinal Endoscopy
R. Bisschops, C. Snaauwaert, E. Toussaint

RBSS
Royal Belgian Society of Surgery
A. De Roover, J. Lerut

RESEARCH GROUPS
GIREM
Belgian Network on Gastrointestinal Regulatory Mechanisms
I. Depoortere

Working Group of Digestive Pathology
A. Hoorens, A. Driessen

BESPHAN
Belgian Society for Paediatric Gastroenterology Hepatology and Nutrition
I. Hoffman, F. Smets

SBNC
Société Belge de Nutrition Clinique
A. Van Gossum

VVKVM
Vlaamse Vereniging voor Klinische Voeding en Metabolism
D. Ysebaert

BIRD
Belgian IBD Research Club
J.F. Rahier, P. Hindryckx

BPC
Belgian Pancreatic Club
M. Delhaye, P. Deprez

BSR
Belgian Society of Radiology, Section of Abdominal Imaging
L. Van Hoe, C. Dragean

BASL
Belgian Group of Digestive Oncology
I. Borbath, M. Peeters

BHPSG
Belgian Microbiota and Helicobacter Study Group
V. Lamy, P. Bonterns, F. Mana

BLIC
Belgian Liver Intestine Committee
O. Detry, J. Pirenne

Belnuc
Belgian Society of Nuclear Medicine
R. Hustinx, C. Deroose

Basic research groups
L. Van Grunsven

Belgian Working Group of Proctology
C. Van Kemseke, D. De Loose

Young BASL
I. Mannaerts

Young VVGE
A. Van Hootegem

ULTRASOUND COURSE
J. Schouten

POSTGRADUATE COURSE
D. De Loose
SATELLITE SYMPOSIA

WEDNESDAY FEBRUARY 20

13:15-14:00 TAKEDA
Endoscopic remission in IBD: fantasy or reality?
Speakers: M. Ferrante (UZ Leuven), M. Duijvestein (AMC Amsterdam)

17:00-17:45 PFIZER
Practical experience with XELJANZ (tofacitinib) in ulcerative colitis.
Speaker: S. Vermeire (UZ Leuven)

THURSDAY FEBRUARY 21

08:15-09:00 BIOGEN - Breakfast Session
Biosimilars: A fuel to Innovation.
Speakers: M. Ferrante (UZ Leuven), L. De Clercq (GZA Antwerp),
J. Gonçalves (Lisbon, Portugal)

08:15-09:00 ABBVIE - Breakfast Session
Towards the eradication of HCV.
Speakers: W. Verlinden (AZ Nikolaas, Sint-Niklaas), R. Bielen & D. Busschots
(Zol, Genk)

12:00-12:45 JANSSEN-CILAG
Targeting IL-23/-12 in Crohn’s disease: experience from across the border.
Speaker: M. Daperno (Torino, Italy)

13:15-14:00 GILEAD
Next challenge on your plate NASH! A multidisciplinary debate.
Speaker: S. Francque (UZ Antwerpen)

FRIDAY FEBRUARY 22

08:15-09:00 ELI LILLY
To triplet or not to triplet: How to optimize sequential treatment in Gastric & GEJ cancer.
Speakers: M. Van den Eynde (UCL Saint-Luc), V. Casneuf (OLV Aalst),
K. Geboes (UZ Gent)

12:15-13:00 SERVIER
New perspectives in the approach of pancreatic cancer.
Speakers: G. Präger (Vienna, Austria), C. Neuzillet (Paris, France)

Our dedication today, is to give her the promise of a tomorrow.
Maria, cancer patient.
INVITED LECTURES

WEDNESDAY FEBRUARY 20

Postgraduate Course:
See program Postgraduate Course p 12-13

BIRD:
Genetics of IBD Disease Severity.
J. Lee (Cambridge, U.K.)
How T cells harm and protect the intestinal mucosa in IBD.
Matthieu Allez (Paris, France)
HSCT in refractory IBD and primary immunodeficiency Disorders.
Matthieu Allez (Saint-Louis, Paris, France)

BPC:
Pain management in chronic pancreatitis: beyond surgery and endotherapy.
M. Puyhaethe / Ziekenhuis Oost Limburg, Genk
EUS-guided main pancreatic ductal drainage: indications, clinical results, complications.
P.H. Deprez / Cliniques Universitaires Saint-Luc, Brussels

Young BASL:
Introduction to cost-effectiveness in hepatology.
D. Van Dipik (UHasselt)
Co-ordinated care - an opportunity to improve patient experience and outcomes when caring for patients with decompensated cirrhosis: the CCCP UZ Leuven project.
W. Laleman (UZLeuven)

THURSDAY FEBRUARY 21

BASL:
Role and indications of albumin in advanced liver disease.
M. Bernardi (Bologna, Italy)
Machine perfusion: a revolution in liver preservation.
C. Watson (Cambridge, UK)

Brohée Prize:
The potential of serum N-glycemics as prognostic biomarkers in liver diseases and liver transplantation.
X. Verhelst (UZ Gent)

BIRD:
Trough levels, drug- sensitive/tolerant ADA: Et Après… Remaining questions and Possible answers.
Xavier Robin (Saint-Etienne, France)
Improving Quality of Care of Endoscopy in IBD: Scoring systems and Chromoendoscopy, How I do it?
Peter Bossuyt (Imelda, Bonheiden)

GIREM:
Ferroptosis and inflammation research in critical illness.
T. Van den Bergh (UAntwerpen)
Using pluripotent stem cells to generate a human.
M. Mahe (Nantes, France)
Gut microbiota and IBD: approaches to improve health.
G. Hold (Sydney, Australia)

INVITED LECTURES

FRIDAY FEBRUARY 22

BSGIE:
Endoscopic management of anemia.
A. May / Offenbach am Main, Germany
Performance measures for small bowel endoscopy (capsule and DAE).
E. Despott / London, UK

BGDO:
Highlights of the year: Upper GI cancers
A. Deleporte / ULB Bordet, Bruxelles
Highlights of the year: Hepato-Bilio-Pancreatic cancers
I. Borbath / UCL Bruxelles
Highlights of the year: Colo-Rectal cancers
M. De Man / UZ Gent

Working Group of Digestive Pathology:
Tumour budding in colorectal cancer.
A.Lugli (Bern, Switzerland)
Applicability of tumour budding in daily practice.
P. Dermetter (UZ Borde)
Reporting of colorectal cancer in polypectomy specimens.
H. Dano (UCL Saint-Luc)
The immnoscore.
J. Galon (Paris, France)
Applicability of immunoscore in daily practice.
L. Verset / ULB Bordet
Molecular pathology of colorectal cancer.
L. Gadeyne, X. Sigaert (UZ Leuven)

BeSPGHAN:
Tolerance induction in food allergic children: can we speed up natural Tolerance.
D. Bullen / UZ Leuven
Diagnosis and management of food protein induced enterocolitis Syndrome.
F. Smets / UCL Saint-Luc
Food allergy tests and gastrointestinal symptoms: not all that glitters is Gold.
A. Van Gasse / ZNA
Cutaneous side effect of drugs in children: diagnosis and differential Diagnosis.
M. Groomer / UZ Brussel
Diaper dermatitis.
H. Lapeer / UZ Gent

Proctology:
See Program Postgraduate Course p 62
Postgraduate Course
ROOM: TEUN

8:30-10:10 - SESSION 1

Moderators: I. Colle (ASZ Aalst & U Gent),
M. Delhaye (ULB Erasme)

- 08:30  Eosinophilic esophagitis. Diagnostic and therapeutic algorithm.
  D. De Looze (UZ Gent)
- 08:55  Barrett's oesophagus. Adequate recognition and treatment of early Dysplasia and/or cancer.
  R. Bisschops (UZ Leuven)
- 09:20  Functional dyspepsia. How to handle it?
  H. De Schepper (UZ Antwerpen)
- 09:45  Percutaneous gastrostomy/jejunostomy. Indications, techniques, follow-up.
  N. Lanthier, T. Moreels (UCL Saint-Luc)

- 10:10 - 10:40 COFFEE BREAK

10:40-12:20 - SESSION 2

Moderators: I. Colle (ASZ Aalst & U Gent),
M. Delhaye (ULB Erasme)

- 10:40  Diagnosis and management of autoimmune pancreatitis.
  I. Schreens (UCL Saint-Luc)
- 11:05  Treatment of acute biliary pancreatitis.
  M. Arvanitaki (ULB Erasme)
- 11:30  Elevated liver tests in pregnancy.
  H. Van Vlierberge (UZ Gent)
- 11:55  Management of variceal (oesophageal and gastric) bleeding.
  T. Gustot (ULB Erasme)

- 12:20 - 13:45 LUNCH

13:45-15:25 - SESSION 3

Moderators: C. Van Kemseke (ULg),
F. Mana (Sint Jan Brussels & Bordet)

- 13:45  Update on celiac disease.
  M. Hiele (UZ Leuven)
- 14:10  Management of IBS: psychotherapy, diet, drugs or bugs?
  T. Vanuytsel (UZ Leuven)
- 14:35  When to stop anti-TNF agents in IBD?
  E. Louis (ULiège)
- 15:00  Colorectal cancer. When is genetic counseling needed?
  K. Dahan (UCL Saint-Luc)

- 15:25 - 16:00 COFFEE BREAK

16:00-17:15 - SESSION 4

Moderators: C. Van Kemseke (ULg),
F. Mana (Sint Jan Brussels & Bordet)

- 16:00  Screening issues for colorectal cancer in Belgium in 2019.
  M. Peeters (UZ Antwerpen)
- 16:25  Endoscopic assessment of colorectal polyps.
  D. Tate (UZ Gent)
- 16:50  Microscopic, lymphocytic and/or collageneous colitis. Diagnosis and treatment.
  F. Baert (AZ Delta Roeselare)
- 17:15  End of the session
Takeda Satellite Symposium

From 13h15 till 14h00
Room LIJN

Endoscopic remission in IBD: fantasy or reality?

Prof. M. Ferrante
UZ Leuven
&
Dr. M. Duijvestein
AMC Amsterdam

13:15 - 14:00 Satellite Symposium TAKEDA:
Endoscopic remission in IBD: fantasy or reality?
Speakers: M. Ferrante (UZ Leuven), M. Duijvestein (AMC Amsterdam)

14:00 Invited Lecture: Genetics of IBD Disease Severity
J. Lee (Cambridge, U.K.)


14:45 I03 Genetic predisposition and thiopurine-induced pancreatitis in inflammatory bowel disease patient.

14:55 I04 Upregulation of IL17-related pathways in affected colon from ulcerative colitis compared to Crohn’s disease.

15:05 Invited Lecture: 2018 Microbiota in the Healthy and IBD.
Jeroen Raes (Leuven)

15:30 - 16:00 COFFEE BREAK
BIRD Basic

16:00-17:00 - SESSION 2: Cell-based research in IBD

Chairs: M. Ferrante (KUL), J.F. Rahier (UCL)

- **16:00 I05** Molecular changes in non-inflamed terminal ileum in patients with ulcerative colitis.

- **16:10 I06** Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment?

- **16:20 I07** Organoids derived of inflammatory intestinal biopsies in ulcerative colitis patients lose their inflammatory transcriptional signature over time.
  K. Arnauts, B. Verstockt, M. Vancamelbeke, S. Vermeire, C. Verfaillie, M. Ferrante / KULeuven

- **16:30** Invited Lecture: How T cells harm and protect the intestinal mucosa in IBD.
  M. Allez (Paris, France)

---

17:00 - 17:45 Satellite Symposium PFIZER:
Practical experience with XELJANZ® (tofacitinib) in ulcerative colitis.
Speaker: S. Vermeire (UZ Leuven)

---

18:00-20:00 BIRD General Assembly
65 years of age and older was higher than those under the age of 65 (4.8 per 100 patient-years versus 2.4 per 100 patient-years). These data suggest a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly (see section 4.4 of the SPC).

Ulcerative colitis serious infections were 2.4 and 3.0 patients with events per 100 patient-years for 5 mg and 10 mg twice daily tofacitinib, respectively. The most commonly reported infections were upper respiratory infections, gastroenteritis, and diverticulitis. Among opportunistic infections, Pneumocystis jirovecii defined using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), and uncommon (≥ 1/1,000 to < 1/100). The most common serious infections resulting in discontinuation of therapy were herpes zoster and pneumonia. Within each frequency grouping, infections were categorized as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), or not known (cannot be estimated from the available data). Within each frequency grouping, infections were categorized as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), or not known (cannot be estimated from the available data).

Immune system disorders

In the clinical studies in UC, changes in ALC observed with tofacitinib treatment were similar to the changes observed in clinical studies in RA. The recommended dose is 10 mg given orally twice daily for induction for 8 weeks and 5 mg given twice daily for maintenance. Patients who do not achieve adequate therapeutic benefit by week 8, the induction dose of 10 mg twice daily can be extended for an additional 8 weeks. In this study, AST elevations greater than 3x ULN were observed in 1.65%, 0.41% and 1.0% of patients taking tofacitinib 5 mg and 10 mg twice daily, respectively. In the RA Phase 3 monotherapy study (0-24 months) (study VI, see section 6.1 of the SPC). Tofacitinib treatment should be interrupted if the infection is controlled. Interruption of dosing may be needed for management of dose-related laboratory abnormalities. Patients with an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.1 of the SPC). Dose interruption and discontinuation: Tofacitinib treatment should be interrupted if serious infections such as sepsis, or opportunistic infections (see section 4.4 of the SPC); Severe hepatic impairment (see section 4.2 of the SPC); Pregnancy and lactation (see section 4.6 of the SPC).

References


---

**BIRD E-POSTERS**

---

**ROOM: WEDNESDAY 20**

---

116 Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients


---

117 Ultra-proactive therapeutic drug monitoring incorporating Infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during INF remission therapy


---

118 Pharmacokinetic and pharmacodynamic evaluation of radiologic healing in Crohn’s patients treated with Infliximab: a TAILORX MRE study


---

119 Pneumocystis jirovecii pneumonia in ibd patients treated with immunomodulator(s)


---

120 Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single centre experience


---

121 Serological markers associated with development of pouchitis after ileal pouch-anal anastomosis


---

122 Effectiveness and safety of vedolizumab maintenance therapy for Inflammatory Bowel Disease: findings from a Belgian registry


---

---

---
I23 The impact of storage time and freeze-thaw cycles on faecal calprotectin concentration in inflammatory bowel disease patients and controls.

I24 Faecal microbiota transplantation as treatment for recurrent clostridium difficile infections: a single centre experience.
C. Caenepeel, A. Schroë, M. Ferrante, S. Vermeire / KU Leuven

I25 The predictive role of gut microbiota in treatment response to vedolizumab and ustekinumab in inflammatory bowel disease.

I26 Bariatric surgery in inflammatory bowel disease: Outcome and safety from a GETAID registry population.

I27 Compliance to vaccination guidelines in patients with immune-mediated inflammatory diseases: a cross-sectional, single-center study.

I28 Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed Crohn’s disease patients.

I29 A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy.

I30 Switch from originator infliximab to biosimilar CT-P13 in inflammatory bowel disease: a retrospective observational two-center cohort study.

M. Puylaert (Ziekenhuis Oost Limburg, Geraart)

I25 Free communications

I26 P01 Pancreatic blunt trauma in children: observations from a monocentric pilot study.

I27 P02 Necrotizing pancreatitis: can MRI diffusion-weighted imaging help in determining infection?
M. Fernandez, M. Arvanitakis, M. Pezzullo, F. Jacobs, J. Devière, M. Delhaye / ULB Erasme

I28 P03 EUS-FNA/FNB of pancreatic solid lesions: accuracy and other quality indicators in two academic endoscopy centres.

I29 Invited Lecture: EUS-guided main pancreatic ductal drainage: indications, clinical results, complications.
P.H. Deprez (UCL Saint-Luc)

I30 15:45-16:10 COFFEE BREAK
16:10-17:00 - SESSION 2

Moderators: P. Eisendrath (ULB Saint-Pierre, Brussels), J.P. Loly (CHU Liège)

Clinical cases

16:10  P04 An unusual finding in a patient with acute pancreatitis: congenital anomaly as a cause?
   L. Jongman, W. Kwanten, S. Van Outryve, S. Vyt, P. Steger / UZ Antwerpen

16:20  Cystic incidentaloma in the pancreas.
   P.H. Deprez, L. Annet, A. Dragean, M. Komuta / UCL Saint-Luc

16:30  P05 Rare retroperitoneal tumor diagnosed by EUS-guided fine needle aspiration.
   L. Bromberg, M. Delhaye, J. Closset, L. Verset, M. Arvanitakis / ULB Erasme

16:40 About an extrinsic gastric compression discovered during the workup of B12 deficiency.

16:50 Initial experience in RFA ablation of pancreatic lesions.
   P.H. Deprez, I. Borbath, M. Komuta, D. Maiter / UCL Saint-Luc

16:50 End of the Session
Abbvie has the great pleasure to invite you to our symposium during the 31st edition of the Belgian Week of Gastroenterology

Towards the eradication of HCV

Thursday February 21, 2019
From 8h15 untill 9h00

Moderators

- Prof. Christophe Moreno
  Erasme Hospital

- Prof. Anja Geerts
  UZ Gent & President of BASL

The 2018 AbbVie bursary winning projects

- Finding the C in psychiatry: the story of an HCV screening program
  (Dr. Wim Verlinden, AZ Nikolaas, Sint-Niklaas)

- Reaching out to the UNdiagnosed people infected with blood borne viral infections (RUNtoBBV)
  (Dr. Rob Bielen & Dana Busschots, ZOL, Genk)

Abbvie has the great pleasure to invite you to our symposium during the 31st edition of the Belgian Week of Gastroenterology
11:00-12:30 - SESSION 2

Moderators: T. Vanwolleghem (UZ Antwerpen), X. Rogiers (UZ Gent)

- 11:00 A06 Combination of glycyrrhizin and n-acetylcysteine: benefit outcome in a murine model of acetaminophen-induced liver failure.

  J. Bert, A. Geerts, A. Vanlander, L. Abreu De Carvalho, F. Berrevoet, R. Troisi, X. Rogiers, H. Van Vlierberghe, X. Verhelst / UZ Gent

- 11:24 A08 The gene signature-MELD score and alcohol consumption determine long-term prognosis of patients with severe alcoholic hepatitis.

- 11:36 A09 Cirrhotic cardiomyopathy does not affect outcome in liver transplantation candidates.

- 11:48-12:30 BELIAC Lecture
  Moderators: O. Detry (ULg), J. Piret (UZ Leuven)
  Machine perfusion: a revolution in liver preservation.
  C. Watson (Cambridge, U.K.)

12:30-14:00 LUNCH
14:00 A10 Severity of NAFLD is associated with both more severe β-cell dysfunction and reduced insulin clearance independently of body weight in a large cohort of non-diabetic subjects: further insights in the causative role of NASH in T2DM development.


14:20 A12 New concepts in liver regeneration mechanisms in human severe alcoholic steatohepatitis.

14:30 A13 Does mucosal inflammation drive recurrence of PSC in liver transplant recipients with ulcerative colitis?
N. Dekkers / Leiden University Medical Center (LUMC), The Netherlands

14:40 A14 Constructing a primary mouse 3D hepatic co-culture model that recapitulates HSC activation during fibrosis.
I. Mannaerts, N. Eysackers, A. Smout, S. Verhulst, S. Leite, T. Roosens, L. Van Grunsven / VUB
16:20 A20 Dissecting the different roles of ORF3 in HEV spread and fecal shedding in a humanized mouse model.

16:30 A21 Non-invasive screening test in physiological conditions for patients with suspected biliary excretion disorders using MRI with hepatospecific contrast.

16:40 Hepatitis C prevalence and screening: summary of accepted E-posters
Presented by BASL Steering Committee member: P. Starkel (UCL Saint-Luc)

16:50 Hepatitis C linkage to care: summary of accepted E-posters
Presented by BASL Steering Committee member: J.P. Mulkay (CHU Saint-Pierre)

17:00 BASL Awards for Best Basic and Clinical work presented

17:10-18:00 BASL General Assembly

A22 Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: Final results of a Swiss prospective study.

A23 Patients with chronic hepatitis C virus infection are at high risk of being lost to follow up. Focused interventions can increase linkage to care.
H. Kymenelen, H. Van De Velde, A. Geerts, H. Van Vlierberge, X. Verheest / UZ Gent

A24 Testing for viral hepatitis B and C by general practitioners in Flanders, Belgium.

A25 Hepatitis C nurse as a case manager in people who inject drugs.

A26 Uptake of treatment for hepatitis C infection in people who inject drugs: the LINK study.

A27 First line screening by fibroscan (transient elastography) in a population at high risk for HCV infection.
F. Desselle / CHC Liège

A28 Myeloid-specific IRE1 alpha deletion reduces tumour development in a non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.

A29 Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach.
**EXHIBITION AREA**

A30 First Belgian Hepatitis E seroprevalence study shows low stable birth-cohort specific seroprevalence until 2014, with recent 2016-2018 increase in single centre estimates.


A31 The prevalence and risk factors of hepatitis B viral infection in Middle Limburg Belgium: the importance of migration.


A32 Computed tomography assisted measurement of visceral adipose tissue volume and subcutaneous adipose tissue volume can differentiate between simple steatosis and nonalcoholic steatohepatitis.


A34 C60 fullerene inhibits fibrosis and initial stages of liver carcinogenesis on rat model of DEN-C44-induced hepatocellular carcinoma.


A35 Relationship between intestinal permeability and inflammation and severity of alcoholic liver disease.


A36 It only takes 25 days to build a hepatitis C care network for people who inject drugs.


A37 Are Ultrasound scans for acute surgical admissions performed within recommended 24 hour window?

S. Barman / Blackpool Victoria Hospital, U. K.
Breakfast Symposium
Thursday, 21st of February
8:15 – 9:00

Chairman:
Prof. Marc FERRANTE

Switching to biosimilar therapy:
a risk or an opportunity?
Prof. Marc FERRANTE

Switching in real life with Subcutaneous Biosimilars: the “Rheuma” Perspective
Doct. Luc DE CLERCQ

Formulation of therapeutic antibodies:
Implication in safety and efficacy
Prof. João GONÇALVES

BIOSIMILARS: A FUEL TO INNOVATION

9:08 - 10:40 - SESSION 3: Frontiers in IBD: Part I

Chairs: C. Reenaers (ULg), F. Baert (AZ Delta, Roeselare)

09:10 Invited Lecture: HSCT in refractory IBD and primary immunodeficiency Disorders.
M. Allez (Paris, France)

09:35 IO8 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision.

09:45 IO9 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single centre experience.

09:55 IO10 Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF orconventional therapy.
Long-term clinical efficacy of Ustekinumab in refractory Crohn’s disease: a multicentre Belgian cohort study.
C. Liefferinckx (1), B. Verstockt (2), A. Gils (3), M. Noman (2), C. Van Kemseke (4),
E. Macken (5), M. De Vos (6), W. Van Moerkercke (7), J. Rahier (8), B. Peter (9),
J. Dutré (6), E. Humbert (10), D. Staessens (11), H. Peeters (12),
P. Van Hootegem (13), E. Louis (4), D. Franchimont (1), F. Baert (1), S. Vermeire (2) / 
[9] Imelda Ziekenhuis, Bonheiden, [10] Ziekenhuis Oost-Limburg - Campus Sint-Jan,

Invited Lecture: Trough levels, drug- sensitive/tolerant ADA: Et Après… Remaining questions and Possible answers.
X. Roblin (Saint-Etienne, France)

Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease.
E. Dreesen (1), F. Baert (2), D. Laharie (3), P. Bossuyt (4), Y. Bouhrin (5),
A. Buisson (6), G. Lambrecht (7), E. Louis (8), B. Oldenburg (9), B. Pariente (10),
M. Plenk (11), C. Van Der Woude (12), G. D’haens (13), S. Vermeire (14),
Bordeaux, France, [4] Imelda Hospital, Bonheiden, [5] Beaujon Hospital, Clichy,
France, [6] Estaing University Hospital, Clermont-Ferrand, France, [7] AZ Damiac,
Oostende, [8] CHU Liège, [9] University Medical Center Utrecht, Netherlands (the),
Netherlands (the), [12] Erasmus Medical Center, Rotterdam, Netherlands (the),
[13] Academic Medical Center, Amsterdam, Netherlands (the), [14] UZ Leuven

A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis.
W. Kantasripitak (1), E. Dreesen (1), I. Defrez (1), S. Stefanovic (2), D. Drobne (2),
<table>
<thead>
<tr>
<th>Time</th>
<th>BELLE EPOQUE</th>
<th>LIJN</th>
<th>TEUN</th>
<th>SANCY</th>
<th>TIFFANY/SHAH</th>
<th>FLORENTINE</th>
<th>HOPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-09.10</td>
<td>Postgraduate Course</td>
<td>08.30-09.10</td>
<td>Postgraduate Course</td>
<td>08.30-10.10</td>
<td>Postgraduate Course</td>
<td>08.30-10.10</td>
<td>Postgraduate Course</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Breakfast Symposium</td>
<td>BIRD Clinical</td>
<td>09.30-10.00</td>
<td>BIRD Clinical</td>
<td>09.30-10.00</td>
<td>BIRD Clinical</td>
<td>09.30-10.00</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Satellite Symposium</td>
<td>Takeda</td>
<td>10.00-10.30</td>
<td>Satellite Symposium</td>
<td>Janssen-Cilag</td>
<td>10.00-10.30</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Satellite Symposium</td>
<td>Abbvie</td>
<td>10.30-11.00</td>
<td>Satellite Symposium</td>
<td>Abbvie</td>
<td>10.30-11.00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Satellite Symposium</td>
<td>BASL</td>
<td>11.00-11.30</td>
<td>Satellite Symposium</td>
<td>BASL</td>
<td>11.00-11.30</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Satellite Symposium</td>
<td>Bsgie</td>
<td>11.30-12.00</td>
<td>Satellite Symposium</td>
<td>Bsgie</td>
<td>11.30-12.00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>12.00-12.45</td>
<td>Satellite Symposium</td>
<td>Janssen-Cilag</td>
<td>12.00-12.45</td>
<td>Satellite Symposium</td>
<td>Janssen-Cilag</td>
<td>12.00-12.45</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>13.30-14.00</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>13.30-14.00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>14.00-14.30</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>14.00-14.30</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>14.30-15.00</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>14.30-15.00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>15.00-15.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>15.00-15.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>15.00-15.15</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>15.45-16.15</td>
<td>Satellite Symposium</td>
<td>Bsgie</td>
<td>15.45-16.15</td>
<td>Satellite Symposium</td>
<td>Bsgie</td>
<td>15.45-16.15</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>Satellite Symposium</td>
<td>Bsgie</td>
<td>16.00-16.30</td>
<td>Satellite Symposium</td>
<td>Bsgie</td>
<td>16.00-16.30</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>16.45-17.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>16.45-17.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>16.45-17.15</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>17.00-17.45</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>17.00-17.45</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>17.00-17.45</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>17.45-18.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>17.45-18.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>17.45-18.15</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>22.45-23.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>22.45-23.15</td>
<td>Satellite Symposium</td>
<td>BeSPGHAN</td>
<td>22.45-23.15</td>
<td>Satellite Symposium</td>
</tr>
</tbody>
</table>
Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy.
E. Hoefkens, L. Pouillon, V. Verheyen, M. Bronswijk, A. Van Olmen, S. Van Dessel, N. Siborgs, P. Bossuyt / Imelda Hospital, Bonheiden

Postoperative endoscopic and clinical recurrence after ileocolonic resection in patients with Crohn’s disease cannot be prevented with high dose vitamin D.

Invited Lecture: Improving Quality of Care of Endoscopy in IBD: Scoring systems and Chromoendoscopy, How I do it?
P. Bossuyt (Imelda, Bonheiden)

Janssen-Sponsored Satellite Symposium at the Belgian Week of Gastroenterology (BWGE) - 31st edition, Antwerp, Belgium

Targeting IL-23/-12 in Crohn’s disease: experience from across the border
Thursday 21 February 2019

Speaker
Prof. Dr. Marco Daperno
Gastroenterology Unit, AO Ordine Mauriziano,Torino, Italy

Moderator
Dr. Catherine Reenaers

Program
12h00 - 12h05: Welcome & Introduction
12h05 - 12h15: Stelara® (ustekinumab) in Crohn’s disease
12h15 - 12h35: Experience from across the border: Prof. Dr. Daperno’s clinical cases
12h35 - 12h45: Q&A session / Conclusion and closing

Venue
Hilton Hotel Antwerp - Conference Center, Room “Lijn”

Janssen-Cilag NV
13:00 – 14:00 GUIDED E-POSTER TOUR

Moderators: P. Dewint (Maria Middelares, Gent & UZ Antwerpen), P. Eisendrath (ULB Saint-Pierre & CUB ULB Brussels)

- **G11** Long term rates of surgery and adenoma recurrence are similar for laterally spreading lesions resected en bloc or by piecemeal endoscopic mucosal resection.

- **G12** Cold snare polypectomy is safe yet under-utilised: an analysis of 281,194 polypectomies by UK endoscopy trainees over 9 years.

- **G13** Eosinophilic esophagitis: clinical, endoscopic and histologic long-term follow-up: a singlecentre retrospective cohort and cross-sectional study.

- **G14** A dedicated competency-based training program in endoscopic resection allows safe and effective resection of complex laterally spreading lesions after 12 months.

- **G15** Natural history of biliary cast syndrome after liver transplantation: a prospective cholangiographic evolution study.

- **G16** Is the short-type single-balloon enteroscope useful for enteroscopy-assisted ERCP in patients with surgically altered anatomy?
  T. Moreels, E. Motté, P. Deprez, H. Pissavaux / UCL Saint-Luc

- **G17** Patient radiation exposure during enteroscopy-assisted ERCP.
  T. Moreels, O. De Ronde, P. Deprez, H. Pissavaux / UCL Saint-Luc

---

**A different approach to hemostasis.**

**NOW available in the USA.**

**Hemospray**

ENDOSCOPIC HEMOSTAT

For more information on Hemospray, visit: hemospray.cookmedical.com

---

Duodenal ulcer bleed images courtesy of Dr. Lars Karlsen, Stavanger University Hospital, Stavanger, Norway.

© COOK 02/2019 ESC-D47189-EN
14:00-14:24 - SESSION 1: Management of colon polyps

Moderators: T. Moreels (UCL Saint-Luc), A. Lemmers (ULB Erasme)

- 14:00 G01 Colorectal polypectomy, are we moving in the right direction? Belgian specific sub-analysis of an international study. J. Geldof (1), D. De Looze (1), L. Desomer (2), D. Tate (1) / [1] UZ Gent, [2] AZ Delta

- 14:12 G02 Cold snare polypectomy for large non-pedunculated polyps. A series of 129 polypectomies. L. Van Overbeke, M. Ferrante, L. Mortier, J. Van Dongen, G. Mertens, S. Liegeois / AZ Sint Maarten, Mechelen

14:24-16:00 - SESSION 2: Quality issues in endoscopy

Moderators: T. Moreels (UCL Saint-Luc), A. Lemmers (ULB Erasme)


- 15:00 Invited Lecture: Endoscopic management of anemia. A. May (Offenbach am Main, Germany)

- 15:30-16:00 COFFEE BREAK

16:00-17:45 - SESSION 3: Innovation in Endoscopy

Moderators: A. Badaoui (UCL Saint-Luc), P. Hindryckx (UZ Gent)

- 16:00 G06 Management of complex biliary leak by endoscopic drainage with transmural or transpapillary-transfistulary access. L. Bromberg, A. Lemmers, M. Fernandez, V. Lucidi, D. Biero, O. Lemoine, J. Devière / ULB Erasme


- 16:36 G09 Gastric per oral endoscopic pyloromyotomy (G-POEM): a retrospective single-center experience. Y. Mourabit, D. Biero, Y. Huberty, M. Arvanitakis, J. Deviere, H. Louis / ULB Erasme


- 17:00 Invited Lecture: Performance measures for small bowel endoscopy (capsule and DAE). E. Despott (London, U.K.)

- 17:30 BSGIE Award Ceremony

- 17:45 End of the Session
09:00-10:30 - SESSION 1

Moderators: B. De Winter (UAntwerpen),
G. Boeckxstaens (KULeuven)

■ 09:00 Invited Lecture: Ferroptosis and inflammation research in critical illness.
T. Vanden Berghe (UAntwerpen)

■ 09:45 B01 Exploring myeloid cell heterogeneity in the resolution of postoperative ileus using single-cell RNA sequencing.

■ 10:00 B02 Effect of a broad-spectrum serine protease inhibitor on intraperitoneal adhesion formation in a murine caecal ligation and puncture model.
P. Plaeke, J. De Man, A. Smet, P. Jorens, G. Hubens, B. De Winter / UAntwerpen

■ 10:15 B03 Intestinal barrier dysfunction in association with fibrosis during experimental acute and chronic colitis in mice.
T. Breugelmans, J. De Man, B. De Winter, A. Smet / UAntwerpen

■ 10:30-11:00 COFFEE BREAK

11:00-12:30 - SESSION 2

Moderators: P. Vanden Berghe (UZ Leuven),
J.P. Timmermans (UAntwerpen)

■ 11:00 Invited Lecture: Using pluripotent stem cells to generate a human.
M. Mahe (Nantes, France)

■ 11:45 B04 Automatic cell tracking in Ca2+ imaging recordings of the enteric nervous system using BSpline Explicit Active Surfaces.

■ 12:00 B05 Cathepsin S-mediated activation of human Mas-related G protein-coupled receptor F: a story of an underrated role for cysteine protease(s) in inflammatory bowel condition?

■ 12:15 B06 Ghrelin as a mediator of metabolic programming of obesity after undernutrition.
S. Sun, K. Corbeels, D. Louis, A. Segers, O. Wang, B. Van Der Schueren, I. Depoortere / KULeuven

■ 12:30-13:30 LUNCH

13:30-15:30 - SESSION 3

Moderators: A. Smet (UAntwerpen), J. Tack (UZ Leuven)

G. Hold (Sydney, Australia)

■ 14:15 B07 Long term effects of Fecal Microbiota Transplantation in Irritable Bowel Syndrome with predominant abdominal bloating: results from a double blind, placebo-controlled, randomized controlled trial.

■ 14:45 B09 Psychological stress triggers a bystander immune response to food antigens leading to neuronal hyperexcitability and visceral hypersensitivity.

■ 15:00 B10 B 10 Mas-related G protein-coupled receptor C11 (MrgrpC11) and its human orthologue MRGPRX1: novel players in visceral hypersensitivity?

■ 15:15 B11 Estrogens modulate the effect of stress on colonic sensitivity and function in a spontaneous rat model of functional gastro-intestinal disorders.

■ 15:30-16:00 COFFEE BREAK
16:00-17:45 - SESSION 4

Moderators: R. Lefebvre (UGent), I. Depoortere (KULeuven)

- **16:00 B12** Serine peptidases as novel target to treat visceral hypersensitivity.
  L. Decraecker (1), B. De Winter (2), V. Cacheux (2), K. Augustyns (2),

- **16:15 B13** Local rectal administration of a serine protease inhibitor reverses visceral hypersensitivity in a rat model for irritable bowel syndrome.
  N. Hanning, H. Ceuleers, M. De Bruyn, I. De Meester, J. Joossens, K. Augustyns,
  H. De Schepper, A. Smet, J. De Man, B. De Winter / UAntwerpen

- **16:30 B14** RvD2 as potential new treatment for visceral hypersensitivity in IBS.
  M. Florens, E. Perna, J. Aguilera-Lizarraga, S. Theofanous, M. Wouters,
  G. Boeckxstaens / KULeuven

- **16:45 B15** Duodenal hyperpermeability and eosinophilia and symptoms in functional dyspepsia patients are reduced by proton pump inhibitors.
  L. Wauters, M. Lambaerts, D. Frings, A. Accarie, J. Toth, R. Farré, G. De Hertogh,
  J. Tack, T. Vanuytsel / UZ Leuven

- **17:00 B16** Codeine induces major motility disorders in healthy volunteers: a randomised double-blind placebo-controlled crossover trial.
  A. Geeraerts (1), H. Geysen (1), L. Ballet (1), C. Hofmans (1), T. Omari (2),

- **17:15 B17** Identification of determinants of Irritable Bowel Syndrome symptom severity in primary care.
  C. Tack (1), K. Van Den Houte (1), F. Carbone (1), E. Colomier (1), E. Clevers (1),

- **17:30 B18** Does measurement of symptoms during a gastric emptying test improve correlation between symptoms and emptying rate?
  R. De Buysscher, K. Van Den Houte, J. Tack, F. Carbone / KULeuven

- **17:45** Concluding remarks
Moderators: C. Van Kemseke (CHU Sart Tilman, ULg), M. Aerts (UZ Brussel)


08:47 C02 Capecitabine: not only hand-foot syndrome. A. Van Oosterwyck, L. Bossuyt, M. Keuppens, S. Van Langendonck, M. Cool, G. Deboever, G. Lambrecht / AZ Damiaan, Oostende

09:04 C03 Rediscovering surgical bile duct exploration in a multimodal approach for common bile duct stones. L. Abreu De Carvalho, S. Van Cleven, O. Uyttebroek, P. Hindryckx, A. Vanlander, X. Rogiers, F. Berrevoet / UZ Gent

09:21 C04 Hemophagocytic lymphohistiocytosis presenting as common gastrointestinal syndromes – think, act and seek immunological alterations. S. Nullens, S. Naegels / ZNA Middelheim, Antwerpen

09:38 C05 Hepatitis B Virus reactivation inducing severe acute hepatitis after Direct-Acting Antiviral Therapy for chronic Hepatitis C virus: A case report. L. Schrooyen, I. Juriena, J. Rigaux / CHU de Charleroi, Hôpital Marie Curie


10:15-10:45 COFFEE BREAK

10:45-12:30 - SESSION 2

Moderators: C. Van Kemseke (CHU Sart Tilman, ULg), M. Aerts (UZ Brussel)


11:02 C08 A liver abscess from India. C. De Herdt (1), S. Bourgeois (2) / [1] U Antwerpen, [2] ZNA Stuivenberg, Borgerhout


12:30-14:00 LUNCH
Dear colleagues and friends,

This year, the Belgian week organises once again a practical, hands on session in ultrasound on Thursday afternoon.

The course will focus on general principles of abdominal ultrasound, knobology and normal anatomy (including gastrointestinal tract, appendix, stomach...). The course aims at trainees in gastroenterology and general medicine with little or no ultrasound experience.

After a short theoretical introduction, participants will be able to practice on healthy volunteers. In the beginning of the session, participants will be divided according to their level of experience.

We would encourage all physicians responsible for the training of gastroenterologists to give their junior fellows the opportunity to participate in this course, to make them (more) familiar with the abdominal ultrasound examination.

---

20:30 : GRANTS 2019 - AWARD CEREMONY

**BWGE Research Grants:**

- Characterization of the intestinal immune system in intestinal fibrosis. Creyns Brecht (KULeuven)
- Unravelling the role of MUC1 and MUC13 in intestinal barrier dysfunction in inflammatory bowel diseases: from bench to bedside. Tom Breugelmans (UAntwerpen)
- Dynamics of macrophage populations, phenotypical changes and liver-gut interactions in the pathogenesis of alcoholic liver disease. Sanne Van Campenhout (UGent)

**Acta Gastroenterologica Belgica – Best Belgian Original Manuscript 2018:**


**BWGE 2019 Prizes:**

- Best Poster Prize Clinical
- Best Poster Prize Basic
- Best Case Report

**BGDO Prize**

**BASL, BIRD, BSGIE and BeSPGHAN Prizes** will be announced but are awarded during their respective sessions.
Before the BGDO session Eli Lilly organises a breakfast symposium at the occasion of the Belgian Week of Gastroenterology.

**To triplet or not to triplet:**
How to optimize sequential treatment in Gastric & GEJ cancer

Breakfast will be offered during this session.

- **Which 1st and 2nd line treatments to combine in sequential treatment?**
  Prof. Marc Van den Eynde (Cliniques Universitaires St. Luc Bruxelles)

- **Sequential treatment in practice**
  Interactive patient case presented by Dr. Veerle Casneuf (O.L.V. Ziekenhuis Aalst)

- **Which sequential treatment suits best for my patient?**
  Prof. Karen Geboes (UZ Gent)

**Moderator of the expert panel:** Prof. Marc Peeters (UZ Antwerpen)

Looking forward to meeting you all for breakfast on 22 February at 08.15.
09:00-10:40 - SESSION 1 : Selected abstracts

Moderators: J.L. Van Laethem (ULB Erasme), K. Geboes (UZ Gent)

09:00  O01 Combining Baseline 18-FDG PET/CT-based Metabolically Active Tumor Volume and Early Detection of Non-Response Significantly Improves Outcome Prediction in Chemoradiotherapy Metastatic Colorectal Cancer.


09:10  O02 Neuroendocrine neoplasms grade 3: prospective overall survival data and survival after platinum-etoposide chemotherapy within an ENETS Center of Excellence.


09:20  O03 Targeting CD70-positive cancer associated fibroblasts to tackle the immune suppressive tumor microenvironment in colorectal cancer.


09:30  O04 Baseline high levels of cell-free DNA and the early increase of at least one mutation are independent prognostic biomarkers for patients with advanced colorectal cancer under regorafenib.

P. Kehagias (1), C. Vandeputte (1), L. Arne (1), H. El Housni (2), A. Deleporte (1), K. Geboes (UZ Gent)
Combined Ga-DOTATATE and FDG PET/CT Imaging Improves Prognostic Stratification in Metastatic Gastroenteropancreatic Neuroendocrine Neoplasias.

Efficacy, safety, and patient-reported outcomes in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400ng/ml: A pooled analysis from REACH and REACH-2 studies.

Highlights of the year: Upper GI cancers
A. Deleporte / IJB Bruxelles

Highlights of the year: Hepato-Bilio-Pancreatic cancers
I. Borbath / UCL Bruxelles

Highlights of the year: Colo-Rectal cancers
M. De Man / UZ Gent

Chairmen : Prof. Ivan Borbath, UCL Brussels
Prof. Jean-Luc Van Laethem, ULB Erasme Brussels
Prof. Chris Verslype, UZ Leuven

• Sequencing strategies in metastatic pancreatic cancer treatment
Prof. Gerald Prager, Head of the Gastro-Intestinal Cancer Program, Medical University of Vienna, Austria

• Targeting the tumour microenvironment for pancreatic ductal adenocarcinoma therapy
Dr. Cindy Neuzillet, Institut Curie – site de Saint Cloud, Paris, France

Looking forward to meeting you all on 22 February at at 12.15.
**O11** Fat Quality: The Handsome Stranger in Esophageal Cancer Prognosis.
M. Anciaux (1), L. Ameye (1), T. Guiot (1), P. Flamen (1), S. Goldman (2).

**O12** Is a single driver gene mutation sufficient for monitoring early response in advanced colorectal cancer?

**O13** The prognostic value of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status in left- and right-sided metastatic colorectal cancer (mCRC): a Belgian population-based study.

**O14** Independent Cohort Validation of the Negative Prognostic Impact of High Visceral Adipose Tissue Density in Advanced Colorectal Cancer.

**O15** Results from the observational COLOGIN study of patients with metastatic colorectal cancer (mCRC) treated with regorafenib for 4 months or more in Belgium.

**O16** Personalised selective internal radiation therapy improves outcomes in refractory intrahepatic cholangiocarcinoma: a multicenter study.

**O17** 90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer.

**O18** 25 years of the Belgian Familial Adenomatous Polyposis Association: results and lessons from a nationwide registry.

**O19** The metabolic clinical risk score (mCRS) as a new prognostic model for surgical decision in patients with colorectal liver metastases.
# WHAT'S NEW IN COLORECTAL CANCER

## 09:00-10:00 - SESSION 1

**Moderators:** A. Hoorens (UZ Gent), P. Baldin (UCL Saint-Luc)

- **09:00**
  - **Invited Lecture:** Tumour budding in colorectal cancer.
  - A. Lugli (Bern, Switzerland)

- **09:30**
  - **Invited Lecture:** Appropriability of tumour budding in daily practice.
  - P. Demetter (ULB Bordet)

**10:00-10:30 COFFEE BREAK**

## 10:30-12:15 - SESSION 2

**Moderators:** A. Hoorens (UZ Gent), P. Baldin (UCL Saint-Luc)

- **10:30**
  - **Invited Lecture:** Reporting of colorectal cancer in polypectomy specimens.
  - H. Dano (UCL Saint-Luc)

- **11:00 R01**
  - **Prognostic significance of CDX2 expression in resected stage II and stage III colorectal cancer.**

- **11:15 R02**
  - **Case report:** Co-existence of serrated adenoma and adenocarcinoma ex goblet cell carcinoid in the appendix.
  - F. Cordier, L. Ferdinande, W. Willaert, A. Hoorens / UZ Gent

- **11:30 R03**
  - **Mesothelial-to-mesenchymal transition in the pathogenesis of colorectal peritoneal metastases.**

- **11:45 R04**
  - **Endoscopic features, pathological correlates and possible origin of foveolar gastric metaplasia presenting as a duodenal polyp.**
  - L. Libbrecht, H. Dano, C. Toussaint, H. Piessevaux / UCL Saint-Luc

- **12:00 R05**
  - **Hepatocellular adenoma, focal nodular hyperplasia and hepatic granulomas in one single patient: a curious association.**

**12:15-14:00 LUNCH**

## 14:00-15:30 - SESSION 3

**Moderators:** A. Driessen (UZ Antwerpen), P. Demetter (ULB Bordet)

- **14:00**
  - **Invited Lecture:** The immunoscore.
  - J. Galon (Paris, France)

- **14:30**
  - **Invited Lecture:** Applicability of immunoscore in daily practice.
  - L. Verset (ULB Bordet)

- **15:00**
  - **Invited Lecture:** Molecular pathology of colorectal cancer.
  - L. Gadeyne, X. Sagaert (UZ Leuven)

**15:30-16:00 COFFEE BREAK**

## 16:00-17:00 - SESSION 4

**Moderators:** A. Driessen (UZ Antwerpen), P. Demetter (ULB Bordet)

- **16:00 R06**
  - **Believe it or not: unusual progression of liver lesions.**

- **16:15 R07**
  - **White tumor in the colon.**
  - Z. Issa, C. Debaille, M. Mignon, D. Augusto, G. Catala, M. Schapira / UCL Jolimont

- **16:30 R08**
  - **Case report of a Kaposi sarcoma involving the upper digestive tract in a 40 year-old kidney transplant patient.**
  - M. Poncin, J. Loly, J. Belaiche, C. Bonvoisin, P. Honoré, J. Somja, S. Defroidmont, E. Louis / CHU Liège

- **16:45 R09**
  - **In pathology we trust! Or shouldn't we?**
  - S. Van Langendonck, G. Van Parys, M. Cool, G. Lambrecht, G. Deboever / AZ Damiaan, Oostende

**17:00**
End of the Session
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

For your pretreated mCRC patients

Make time for more moments that matter
Demonstration and discussion about implementation of key indicators of performance in small bowel endoscopy

Moderators: R. Bischops (UZ Leuven), D. Blero (ULB Erasme), P. Hendryckx (UZ Gent)

Live endoscopy from ULB Erasme:
5 cases will be scheduled in 2 rooms:
- Spiral enteroscopy: M. Arvanitakis
- Double balloon enteroscopy: E. Despott
- Single balloon: T. Moreels
- Small bowel capsule endoscopy pictures during live: P. Hendryckx
- EMR duodenum: A. May

Improving the quality of life of people with IBD*

Janssen’s commitment to researching and developing new, innovative treatments puts us at the forefront when it comes to improving clinical outcomes and quality of life for people with inflammatory bowel disease (IBD).

IBD is a group of chronic conditions affecting the bowel, such as Crohn’s disease and ulcerative colitis.

We are Janssen. We collaborate with the world for the health of everyone in it.

For more information, visit www.janssen.com/belgium

*Inflammatory Bowel Disease

The image features a model and is used for illustrative purposes only.

Janssen-Cilag NV
Moderators: S. Vande Velde (UZ Gent), P. Bontems (HUDERF)

13:30 Invited Lecture: Tolerance induction in food allergic children: can we speed up natural tolerance.
D. Bullen / UZ Leuven

14:00 Invited Lecture: Diagnosis and management of food protein induced enterocolitis syndrome.
F. Smets / UCL Saint-Luc

14:30 Invited Lecture: Food allergy tests and gastrointestinal symptoms: not all that glitters is gold.
A. Van Gasse / ZNA

15:00-15:30 COFFEE BREAK

15:30 - 16:00 SESSION 2: Abstracts

Moderators: F. Smets (UCL Saint-Luc), B. Hauser (UZ Brussel)

15:30 K01 Clinical pre-test probability for celiac disease and value added reporting of IgA tissue transglutaminase antibodies in the pediatric setting.

15:40 K02 Switching from infliximab originator to a biosimilar is safe in paediatric patients with inflammatory bowel disease without affecting efficacy, pharmacokinetics and immunogenicity.

15:50 K03 Efficacy and safety of bismuth based quadruple therapy for Helicobacter Pylori eradication in children: an interim analysis.

16:00 Invited Lecture: Cutaneous side effect of drugs in children: diagnosis and differential diagnosis
M. Grosber / UZ Brussel

16:30 Invited Lecture: Diaper dermatitis
H. Lapeer / UZ Gent

17:00 General Assembly
Session 1: Peri-anal Crohn’s disease and selected abstracts

■ 14:00  M01  Fistula-tract Laser Closure (FiLaCTM) as a last resort for treatment-resistant perianal fistula: case series and review of the literature.
N. De Hous (1), C. De Gheldere (2), S. Van Den Broeck (1), N. Komen (1)  

■ 14:15  M02  Radiofrequency ablation (Rafaelo Procedure) as treatment for haemorrhoids, a pilot study.
M. De Visschere, D. De Looze, D. Van De Putte, P. Pattyn / UZ Gent


■ 14:30  Invited Lecture: Clinical manifestations of peri-anal Crohn’s disease.
D. De Looze / UZ Gent

M. Spinhoven, H. De Schepper / UZ Antwerpen

■ 15:10  Invited Lecture: Medical treatment in peri-anal Crohn’s disease.
G. Dhaens / AML Amsterdam, The Netherlands

A. Dhoore / UZ Leuven

■ 16:00  End of the program
Notes
Notes
With the Kind Support of our Partners, BWGE becomes possible! THANK YOU

PLATINUM

GILEAD

Janssen

SERVIER

Takeda

GOLD

abbvie

Bayer

Biogen

Lilly

MSD

Pfizer

SILVER

BOSTON SCIENTIFIC • BOUCART MEDICAL • COOK MEDICAL • NORGINE • OLYMPUS • ONIS • PENTAX • Sandid

BRONZE

ACERTYS • ACTA GASTROENTEROLOGICA BELGICA • AMGEN • ARKOPHARMA • BIOCODEX • BTG Biocompatibles • CANCER REGISTRY • CELGENE • Dr FALK PHARMA • ECHOSENS • GBS-VBS • GE Healthcare • GENFIT (NASH) • INTERCEPT • LABORIE • LAMEPRO • MEAD JOHNSON NUTRITION • MEDISQUARE • MUNDIPHARMA • MYLAN • NESTLE • REVOGAN • ROCHE • RVC • SELINION • TILMAN • TRAMEDICO • VMC-MEDIQUALITY • W.L. GORE & Associates • WHAT’S UP DOC

ASSOCIATIONS

F.A.P.A. • CHAC • Chrohn FR • Chrohn NL


BWGE Event Coordination : DME Events • Anne-France De Meyer • 57 av. G Demey 1160 Bruxelles • anne.france.de.meyer@dme-events.eu • Tel : 0477 27 00 45

www.bwge.be